Experience

2023 05 11 NeuExcell Therapeutics Announces 15 Million Series Pre-A

NeuExcell Therapeutics Announces $15 Million Series Pre-A+

May 15, 2023

Cooley advised NeuExcell Therapeutics, a neurodegenerative disease gene therapy company, on its $15 million+ Series Pre-A+ financing round.

Read more

Related contacts

Christina Zhang
Partner, Shanghai
Lunga Su
Associate, Shanghai
Teresa Yang
Legal Consultant, Shanghai

Related Practices & Industries

Structure Therapeutics – $185.3 Million IPO

February 9, 2023

San Francisco – February 9, 2023 Cooley advised Structure Therapeutics, a clinical-stage global biopharmaceutical company, on its $185.3 million initial public offering, including the full exercise of the underwriters’ option to purchase additional American depositary shares. Lawyers Charlie Kim, Patrick Loofbourrow, Andrew Harline and Su Lian Lu led the Cooley team.

The offering marks the first sizable US life sciences IPO this year. Structure Therapeutics will use the proceeds to develop new oral therapies for the treatment of various diseases, including those impacting the metabolic, cardiovascular and pulmonary systems. Its lead product candidate targets Type 2 diabetes and obesity.

Structure Therapeutics aims to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise, enabling it to build a pipeline of product candidates. The company currently focuses on G-protein-coupled receptors as a therapeutic target class.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

Related contacts

Charlie Kim
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Andrew Harline
Partner, Singapore
Su Lian Lu
Special Counsel, Los Angeles Santa Monica
Xander Lee
Partner, Los Angeles Santa Monica
Jie Zhang
Partner, Hong Kong
Phil Mitchell
Partner, New York
Aaron Pomeroy
Partner, Colorado
Carlos Ramirez
Partner, San Diego
Ryan Blair
Partner, San Diego
Joshua Mates
Partner, San Francisco
Mark Ballantyne
Partner, Reston
Nicola Squire
Partner, London
Francis Wheeler
Partner, Colorado
Will Cai
Partner, Hong Kong
Thomas Welk
Senior Counsel, San Diego
Natasha Leskovsek
Of Counsel, Washington DC
Dani Nazemian
Special Counsel, San Diego
Randy Sabett
Special Counsel, Washington DC
Bin Wang
Special Counsel, Palo Alto
Rebecca Ross
Special Counsel, Washington DC
Lisa Yuan
Special Counsel, Beijing
Jennifer Shanley
Special Counsel, New York
Christine Turner
Associate, Colorado
Vince Flynn
Associate, San Diego
Ivy Wang
Associate, Shanghai
Rick Jantz
Associate, Los Angeles Santa Monica
Yuan Dai
Associate, Shanghai
Cara Buchicchio
Associate, New York
Megan Drill
Associate, San Diego
Daniel Gillon
Associate, San Diego
Dionne A. Thomas
Associate, San Diego
Cristina Ferruolo
Associate, San Diego
Brian Lau
International Legal Project Manager, Hong Kong
Jessica Wade
Paralegal Specialist, San Diego
Kate Walther
Paralegal Specialist, San Diego
Lunga Su
Associate, Shanghai
Christine S. Kim
Associate, San Diego
Andy Zachrich
Associate, San Diego

Related Practices & Industries

InxMed Raises $50 Million Series B

March 10, 2022

Cooley advised InxMed on its $50 million Series B financing. Partner Christina Zhang led the team advising InxMed, which is a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors.

CS Capital led the round, with participation from AIHC Fund, Growth Fund and Hosencare Fund, as well as existing investor Ennovation Ventures. InxMed will use the funds to accelerate ongoing clinical trials of IN10018 for multiple cancer types in the US and China, to advance more stroma-targeting pipelines into clinics this year, and to strengthen research and development capabilities in Nanjing, China.

Related contacts

Christina Zhang
Partner, Shanghai
Monica Xu
Counsel, Shanghai
Lunga Su
Associate, Shanghai

Related Practices & Industries

EpimAb Biotherapeutics Raises $120 Million Series C

March 23, 2021

Cooley advised EpimAb Biotherapeutics, a clinical-stage biotech company specializing in bispecific antibody development, on its $120 million Series C financing. China Merchants Bank International and Mirae Asset Financial Group co-led the round, which also included participation by Hony Capital, Cormorant Asset Management and other new investors, as well as existing investors such as Decheng Capital, SDIC Fund and Sherpa Healthcare Partners. EpimAb will use the new capital for the ongoing clinical development of three of its clinical assets and to expand its pipeline of novel bispecific antibodies and other biologics. Partner James Lu led the team advising EpimAb on the financing round.

Related contacts

Monica Xu
Counsel, Shanghai
Lunga Su
Associate, Shanghai

Related Practices & Industries